Publications by authors named "Barbara Helfrich"

Claim this Profile
E
Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
Barbara A Helfrich, Dexiang Gao, Paul A Bunn

Lung Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
Hannah A Scarborough, Barbara A Helfrich, Matias Casás-Selves, Alwin G Schuller, Shaun E Grosskurth

Clin Cancer Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Barbara A Helfrich, Jihye Kim, Dexiang Gao, Daniel C Chan, Zhiyong Zhang

Mol Cancer Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
Murry W Wynes, Trista K Hinz, Dexiang Gao, Michael Martini, Lindsay A Marek, Barbara A Helfrich

Clin Cancer Res· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
D Ross Camidge, Margaret Skokan, Porntip Kiatsimkul, Barbara Helfrich, Xian Lu

Cancer· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.
Matias Casás-Selves, Jihye Kim, Zhiyong Zhang, Barbara A Helfrich, Dexiang Gao

Cancer Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZEB1-responsive genes in non-small cell lung cancer.
Robert M Gemmill, Joëlle Roche, Vincent A Potiron, Patrick Nasarre, Michael Mitas, Barbara A Helfrich

Cancer Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
Kathryn E Ware, Marianne E Marshall, Lydia R Heasley, Lindsay Marek, Trista K Hinz, Barbara A Helfrich

PLoS One· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.
Lindsay Marek, Kathryn E Ware, Alexa Fritzsche, Paula Hercule, Wallace R Helton, Barbara A Helfrich

Mol Pharmacol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.
Barbara A Frederick, Barbara A Helfrich, Christopher D Coldren, Di Zheng, Dan Chan

Mol Cancer Ther· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Barbara A Helfrich, David Raben, Marileila Varella-Garcia, Dan Gustafson, Daniel C Chan

Clin Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.
Christopher D Coldren, Barbara A Helfrich, Samir E Witta, Michio Sugita, Razvan Lapadat

Mol Cancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
Samir E Witta, Robert M Gemmill, Fred R Hirsch, Christopher D Coldren, Karla Hedman, Barbara Helfrich

Cancer Res· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New lung cancer drugs from bradykinin antagonists.
John M Stewart, Lajos Gera, Daniel C Chan, Eunice J York, Laimute T Stewart, Barbara Helfrich

Chest· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bradykinin antagonists as new drugs for prostate cancer.
John M Stewart, Daniel C Chan, Vitalija Simkeviciene, Paul A Bunn, Barbara Helfrich

Int Immunopharmacol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Daniel C Chan, Lajos Gera, John M Stewart, Barbara Helfrich, Tom Limin Zhao

Clin Cancer Res· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Fred R Hirsch, Barbara Helfrich, Wilbur A Franklin, Marileila Varella-Garcia, Daniel C Chan

Clin Breast Cancer· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism.
Daniel Chan, Lajos Gera, John Stewart, Barbara Helfrich, Marileila Verella-Garcia

Proc Natl Acad Sci U S A· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bradykinin-related compounds as new drugs for cancer and inflammation.
John M Stewart, Lajos Gera, Daniel C Chan, Paul A Bunn, Eunice J York, Barbara Helfrich

Can J Physiol Pharmacol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Daniel C Chan, Keith A Earle, Tom L M Zhao, Barbara Helfrich, Chan Zeng

Clin Cancer Res· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor family in lung cancer and premalignancy.
Wilbur A Franklin, Robert Veve, Fred R Hirsch, Barbara A Helfrich, Paul A Bunn

Semin Oncol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
David Raben, Barbara A Helfrich, Dan Chan, Gary Johnson, Paul A Bunn

Semin Oncol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
Paul A Bunn, Daniel C Chan, Keith Earle, Tom L M Zhao, Barbara Helfrich

Semin Oncol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis